» Articles » PMID: 16010174

A Prognostic Model for HIV Seroconversion Among Injection Drug Users As a Tool for Stratification in Clinical Trials

Overview
Date 2005 Jul 13
PMID 16010174
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The main goal of this study was to construct a prognostic model for HIV seroconversion among injection drug users (IDUs) using easy-to-measure risk indicators.

Design: Cox proportional hazards regression modeling was used for risk stratification in a heterogeneous population of IDUs with regards to HIV risk-taking behaviors.

Methods: Subjects were recruited in a prospective cohort of IDUs followed between September 1992 and October 2001. A total of 1602 men, seronegative at enrollment with at least 1 follow-up visit, were included in the analyses. Only variables that consistently predict HIV seroconversion in several settings were considered. The final model was used to assign a risk score for each participant.

Results: Three risk indicators were included in the risk score to predict HIV seroconversion: unstable housing, average cocaine injections per day, and having shared a syringe with a known HIV-positive partner. Kaplan-Meier survival functions were generated and risk score values stratified in 3 groups. HIV incidence rates per 100 person-years were as follows: 0.91 (95% CI, 0.55-1.52) for the low-risk group, 3.10 (95% CI, 2.49-3.84) for the moderate-risk group, and 7.82 (95% CI, 6.30-9.73) for the high-risk group (log-rank P value < 0.0001).

Conclusion: If validated in other settings, this risk score may improve the prediction of outcome and allow more accurate stratification in clinical trials.

Citing Articles

Persons who inject drugs (PWID) retain functional NK cells, dendritic cell stimulation, and adaptive immune recall responses despite prolonged opioid use.

Tomescu C, Colon K, Smith P, Taylor M, Azzoni L, Metzger D J Leukoc Biol. 2020; .

PMID: 33289158 PMC: 8244827. DOI: 10.1002/JLB.5A0920-604R.


Real-World Eligibility for HIV Pre-exposure Prophylaxis Among People Who Inject Drugs.

Picard J, Jacka B, Hoj S, Laverdiere E, Cox J, Roy E AIDS Behav. 2020; 24(8):2400-2408.

PMID: 31997057 PMC: 10710293. DOI: 10.1007/s10461-020-02800-w.


A Meta-analysis of the Association Between Needle Exchange Programs and HIV Seroconversion Among Injection Drug Users.

Mir M, Akhtar F, Zhang M, Thomas N, Shao H Cureus. 2018; 10(9):e3328.

PMID: 30473961 PMC: 6248663. DOI: 10.7759/cureus.3328.


S100A14 Is Increased in Activated NK Cells and Plasma of HIV-Exposed Seronegative People Who Inject Drugs and Promotes Monocyte-NK Crosstalk.

Colon K, Speicher D, Smith P, Taylor M, Metzger D, Montaner L J Acquir Immune Defic Syndr. 2018; 80(2):234-241.

PMID: 30422902 PMC: 6331283. DOI: 10.1097/QAI.0000000000001911.


Innate activation of MDC and NK cells in high-risk HIV-1-exposed seronegative IV-drug users who share needles when compared with low-risk nonsharing IV-drug user controls.

Tomescu C, Seaton K, Smith P, Taylor M, Tomaras G, Metzger D J Acquir Immune Defic Syndr. 2014; 68(3):264-73.

PMID: 25514793 PMC: 4329050. DOI: 10.1097/QAI.0000000000000470.